EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advances in organ-on-chip for drug transporter study: Key insights and hurdles

Isy Petit, Jean-Sébastien Bernard, Quentin Faucher, Dorian Chastagner, Hélène Arnion, Florent Di Meo, Nicolas Védrenne

Drug Metabolism and Disposition · 2026-06 · 54 (6) · 100312

DOI: 10.1016/j.dmd.2026.100312 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Metabolism and Disposition, 2026-06. Verfasst von Isy Petit und 6 weiteren Autor:innen. Beteiligte Einrichtung: U1248 Pharmacology & Transplantation, Inserm, Université de Limoges, Limoges, France. Hauptthemen laut MEDLINE: Membrane Transport Proteins, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Conseil Régional Aquitaine, Nierstichting, H2020 Marie Skłodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membrane transporters play a central role in the absorption, distribution, metabolism, and elimination of drugs. Beyond drug handling, these transporters regulate the transport of endogenous metabolites, contributing to physiological homeostasis. Their activity is regulated not only by intrinsic cellular mechanisms but also by signals from distant organs. Understanding these processes is crucial for accurately predicting both local and systemic pharmacokinetics, as transporter function influences drug concentrations and effects at target tissues and throughout the organism. However, most current in vitro models do not recapitulate interorgan interactions or the dynamic regulation of transporter function. Microphysiological systems, particularly organ-on-chip, offer a promising approach to studying transporter biology in a more integrated and physiologically relevant context. This review provides an overview of the development and application of organ-on-chip technologies to investigate drug transporters and their regulation. Although significant technical progress has been made, these systems often remain focused on engineering or industrial goals, with limited impact on fundamental biological questions. Moreover, the high degree of customization and widespread use of homemade organ-on-chip models, with diverse materials, geometries, and cell sources, have created substantial barriers to reproducibility and cross-laboratory comparison. We here assess the current state of the field and identify gaps in modeling transporter regulation and interorgan communication. We also explore the potential of organ-on-chip to advance our understanding of systemic pharmacology. This review aims to reposition organ-on-chip platforms not only as technological demonstrators but also as experimental systems capable of generating new biological insights into transporter function and organ crosstalk. SIGNIFICANCE STATEMENT: Membrane transporters are central regulators of drug disposition and systemic homeostasis, yet their interorgan regulation remains poorly captured by conventional models. This review highlights how organ-on-chip technologies can bridge this gap, enabling mechanistic investigation of transporter function and advancing predictive, human-relevant pharmacology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane Transport ProteinsLab-On-A-Chip DevicesHumansMicrophysiological SystemsAnimalsPharmaceutical PreparationsBiological TransportPharmacokinetics

Stichwörter der Autor:innen

Drug transportersInter-organ communicationOrgan-on-chip

Substanzen

Membrane Transport ProteinsPharmaceutical Preparations

Autor:innen und Institutionen

  • U1248 Pharmacology & Transplantation, Inserm, Université de Limoges, Limoges, France.
  • Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • UAR2015/US42 Integrative Biology Health Chemistry and Environment BISCEm, CNRS, Inserm, CHU Limoges, Université de Limoges, Limoges, France.
  • U1248 Pharmacology & Transplantation, Inserm, Université de Limoges, Limoges, France; UAR2015/US42 Integrative Biology Health Chemistry and Environment BISCEm, CNRS, Inserm, CHU Limoges, Université de Limoges, Limoges,…
  • U1248 Pharmacology & Transplantation, Inserm, Université de Limoges, Limoges, France. Electronic address: nicolas.vedrenne@unilim.fr.

Förderung

  • Conseil Régional Aquitaine
  • Nierstichting
  • H2020 Marie Skłodowska-Curie Actions
  • Agence Nationale de la Recherche
  • Kidney Foundation of Canada
  • Google
  • HORIZON EUROPE Framework Programme

Zitieren

APA

Petit, I., Bernard, J. S., Faucher, Q., Chastagner, D., Arnion, H., Di Meo, F., & Védrenne, N. (2026). Advances in organ-on-chip for drug transporter study: Key insights and hurdles. Drug Metabolism and Disposition, 54(6), 100312. https://doi.org/10.1016/j.dmd.2026.100312

Vancouver

Petit I, Bernard JS, Faucher Q, Chastagner D, Arnion H, Di Meo F, et al. Advances in organ-on-chip for drug transporter study: Key insights and hurdles. Drug Metabolism and Disposition. 2026;54(6):100312. doi:10.1016/j.dmd.2026.100312

BibTeX
@article{Petit2026,
  author = {Petit, Isy and Bernard, Jean-Sébastien and Faucher, Quentin and Chastagner, Dorian and Arnion, Hélène and Di Meo, Florent and Védrenne, Nicolas},
  title = {Advances in organ-on-chip for drug transporter study: Key insights and hurdles},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {6},
  pages = {100312},
  doi = {10.1016/j.dmd.2026.100312}
}
Kostenlos starten →